Wellgistics Targets the Booming Weight-Loss Drug Market with a New Muscle Preservation Product
New York, Monday, 9 March 2026.
As the weight-loss drug market races toward a projected $201 billion by 2030, Wellgistics has launched Forzet, an over-the-counter solution specifically designed to combat treatment-induced muscle loss.
Addressing the Primary Side Effect of GLP-1 Agonists
Wellgistics Health, Inc. (NASDAQ:WGRX) officially launched Forzet on March 9, 2026, targeting a critical clinical gap in the weight-loss sector [1]. While GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have revolutionized obesity treatment, they are frequently associated with significant muscle degradation [1]. The GLP-1 market was valued at $70 billion in 2025 and is projected by Grandview Research to reach $201 billion by 2030, representing a projected growth of 187.143 percent [1]. Wellgistics aims to capture a share of this expanding market by offering a proprietary formulation intended to preserve muscle mass during therapy and prevent weight regain upon discontinuation [1].
Strategic Distribution and AI Integration
To maximize the commercial reach of Forzet, Wellgistics is leveraging its established technological infrastructure [1]. The company’s PharmacyChain blockchain platform currently connects over 6,500 pharmacies and more than 200 manufacturers [1][2]. By integrating its EinsteinRx artificial intelligence platform, Wellgistics plans to utilize point-of-sale pop-ups to recommend Forzet to patients picking up GLP-1 prescriptions [1]. The product will initially be rolled out to physicians, prescribing pharmacists, and members of the Wellgistics Pharmacy Network [1].
Expanding the Ecosystem Through Telehealth
Recognizing the need for comprehensive patient support, Wellgistics has simultaneously broadened its digital health capabilities [2]. On February 11, 2026, the company announced an expanded partnership with Tollo Health, LLC [2]. Tollo Health’s newly formed subsidiary, TolloCare, LLC, provides telehealth services specifically targeting GLP-1 and Long COVID patients [2]. This expansion grants Wellgistics access to a telemedicine network featuring over 5,000 physicians, as well as a mental health AI application developed by a San Francisco Bay Area startup [2].